Jean-Sebastien Guillamo

List of Publications by Year
in descending order

31 papers	2,314 citations	361413 20 h-index	414414 32 g-index
32 all docs	32 docs citations	32 times ranked	3180 citing authors

#	Article	IF	Citations
1	Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, ¹⁸F-FMISO PET, and ¹⁸F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma. Journal of Nuclear Medicine, 2021, 62, 1349-1356.	5.0	14
2	Reversible â€œears of the lynxâ€•sign in Marchiafavaâ€“Bignami disease. Acta Neurologica Belgica, 2019, 119, 275-277.	1.1	3
3	Comparison between MRI-derived ADC maps and 18FLT-PET in pre-operative glioblastoma. Journal of Neuroradiology, 2019, 46, 359-366.	1.1	5
4	Hypoxia Imaging and Adaptive Radiotherapy: A State-of-the-Art Approach in the Management of Glioma. Frontiers in Medicine, 2019, 6, 117.	2.6	40
5	Promoter Hypermethylation of Genes Encoding for RASSF/Hippo Pathway Members Reveals Specific Alteration Pattern in Diffuse Gliomas. Journal of Molecular Diagnostics, 2019, 21, 695-704.	2.8	11
6	Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG). Oncologist, 2018, 23, 524.	3.7	30
7	Allergic conditions and risk of glioma and meningioma in the CERENAT case-control study. Journal of Neuro-Oncology, 2018, 138, 271-281.	2.9	15
8	Interactions between glioma and pregnancy: insight from a 52-case multicenter series. Journal of Neurosurgery, 2018, 128, 3-13.	1.6	34
9	In Vivo Relationship Between Hypoxia and Angiogenesis in Human Glioblastoma: A Multimodal Imaging Study. Journal of Nuclear Medicine, 2017, 58, 1574-1579.	5.0	38
10	[18F]-FMISO PET study of hypoxia in gliomas before surgery: correlation with molecular markers of hypoxia and angiogenesis. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1383-1392.	6.4	78
11	FMISO-PET-derived brain oxygen tension maps: application to glioblastoma and less aggressive gliomas. Scientific Reports, 2017, 7, 10210.	3.3	20
12	Pseudotumoral brain lesions: MRI review. Acta Neurologica Belgica, 2017, 117, 17-26.	1.1	4
13	Prognostic value of healthâ€related quality of life for death risk stratification in patients with unresectable glioblastoma. Cancer Medicine, 2016, 5, 1753-1764.	2.8	12
14	Immunotherapy with CpGâ€<scp>ODN</scp> in neoplastic meningitis: A phase I trial. Cancer Science, 2015, 106, 1212-1218.	3.9	24
15	Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas. Neurology, 2015, 85, 1325-1331.	1.1	34
16	Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastrophe. Oncotarget, 2015, 6, 2101-2119.	1.8	30
17	IDH1R132HMutation Increases U87 Glioma Cell Sensitivity to Radiation Therapy in Hypoxia. BioMed Research International, 2014, 2014, 1-5.	1.9	13
18	Mobile phone use and brain tumours in the CERENAT case-control study. Occupational and Environmental Medicine, 2014, 71, 514-522.	2.8	144

#	Article	IF	Citations
19	Implanted Carmustine Wafers Followed by Concomitant Radiochemotherapy to Treat Newly Diagnosed Malignant Gliomas: Prospective, Observational, Multicenter Study on 92 Cases. Annals of Surgical Oncology, 2013, 20, 2065-2072.	1.5	38
20	Detection of glioblastoma response to temozolomide combined with bevacizumab based on ÂµMRI and ÂµPET imaging reveals [18F]-fluoro-l-thymidine as an early and robust predictive marker for treatment efficacy. Neuro-Oncology, 2013, 15, 41-56.	1.2	41
21	O⁶â€methylguanineâ€DNA methyltransferase (MGMT) promoter methylation and low MGMTâ€encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide. Cancer, 2012, 118, 4545-4554.	4.1	79
22	Targeting the erythropoietin receptor on glioma cells reduces tumour growth. Experimental Cell Research, 2011, 317, 2321-2332.	2.6	15
23	Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial. Journal of Clinical Oncology, 2011, 29, 3050-3055.	1.6	196
24	MRI assessment of hemodynamic effects of angiopoietin-2 overexpression in a brain tumor model. Neuro-Oncology, 2009, 11, 488-502.	1.2	15
25	Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma. Clinical Cancer Research, 2009, 15, 3697-3704.	7.0	69
26	Radiotherapy for Glioblastoma in the Elderly. New England Journal of Medicine, 2007, 356, 1527-1535.	27.0	736
27	Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro-Oncology, 2007, 9, 412-423.	1.2	149
28	Antiangiogenic Therapy Against Experimental Glioblastoma Using Genetically Engineered Cells Producing Interferon-l±, Angiostatin, or Endostatin. Human Gene Therapy, 2003, 14, 883-895.	2.7	46
29	Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): A retrospective study of 104 patients. Brain, 2003, 126, 152-160.	7.6	242
30	Invasion of human glioma biopsy specimens in cultures of rodent brain slices: a quantitative analysis. Journal of Neurosurgery, 2002, 97, 169-176.	1.6	41
31	Brain stem gliomas. Current Opinion in Neurology, 2001, 14, 711-715.	3.6	94